Immune cells: potential carriers or agents for drug delivery to the central nervous system

Drug delivery systems (DDS) have recently emerged as a promising approach for the unique advantages of drug protection and targeted delivery. However, the access of nanoparticles/drugs to the central nervous system (CNS) remains a challenge mainly due to the obstruction from brain barriers. Immune c...

Full description

Saved in:
Bibliographic Details
Published in:Military medical research 2024-03, Vol.11 (1), p.19-19, Article 19
Main Authors: Zhang, Shan-Shan, Li, Ruo-Qi, Chen, Zhong, Wang, Xiao-Ying, Dumont, Aaron S, Fan, Xiang
Format: Article
Language:English
Subjects:
Antigens
Blood vessels
Blood-Brain Barrier
Brain
Cell adhesion & migration
Central nervous system
Central Nervous System Diseases - drug therapy
Chemokines
Drug Delivery Systems
Drugs
Epilepsy
Fatty acids
Glycoproteins
Homeostasis
Humans
Immune cells
Leukocytes
Ligands
Medical research
Multiple sclerosis
Nanoparticles
Nanoparticles - therapeutic use
Nervous system
Physiology
Spinal cord
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug delivery systems (DDS) have recently emerged as a promising approach for the unique advantages of drug protection and targeted delivery. However, the access of nanoparticles/drugs to the central nervous system (CNS) remains a challenge mainly due to the obstruction from brain barriers. Immune cells infiltrating the CNS in the pathological state have inspired the development of strategies for CNS foundation drug delivery. Herein, we outline the three major brain barriers in the CNS and the mechanisms by which immune cells migrate across the blood-brain barrier. We subsequently review biomimetic strategies utilizing immune cell-based nanoparticles for the delivery of nanoparticles/drugs to the CNS, as well as recent progress in rationally engineering immune cell-based DDS for CNS diseases. Finally, we discuss the challenges and opportunities of immune cell-based DDS in CNS diseases to promote their clinical development.
ISSN:2054-9369
2095-7467
2054-9369
DOI:10.1186/s40779-024-00521-y